Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP: 1.Advances in MDS Classification and Molecular Understanding

EP: 2.Choosing MDS Therapies: Risk-Based Approaches

EP: 3.Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP: 4.ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Now Viewing

EP: 5.Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP: 6.HMA Persistence and Effectiveness in Higher Risk MDS

EP: 7.Innovations and Future Directions in Higher Risk MDS Treatments

EP: 8.Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP: 9.Oral vs. IV HMAs: Considerations and Patient Guidance

EP: 10.Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

• For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population?
• How do social support and logistical factors, such as the ability to access clinics for extended periods for injectable hypomethylating agents (HMAs), affect treatment adherence and outcomes in patients with higher-risk MDS?
• Given that HMAs are the backbone of treatment for higher-risk MDS, how do oral options such as decitabine-cedazuridine and other emerging therapies address the need for more convenient administration while maintaining efficacy?